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Abstract
Background: To date, fasting state- and different oral glucose tolerance test (OGTT)-derived measures are used to estimate
insulin release with reasonable effort in large human cohorts required, e.g., for genetic studies. Here, we evaluated twelve
common (or recently introduced) fasting state-/OGTT-derived indices for their suitability to detect genetically determined b-
cell dysfunction.
Methodology/Principal Findings: A cohort of 1364 White European individuals at increased risk for type 2 diabetes was
characterized by OGTT with glucose, insulin, and C-peptide measurements and genotyped for single nucleotide
polymorphisms (SNPs) known to affect glucose- and incretin-stimulated insulin secretion. One fasting state- and eleven
OGTT-derived indices were calculated and statistically evaluated. After adjustment for confounding variables, all tested SNPs
were significantly associated with at least two insulin secretion measures (p#0.05). The indices were ranked according to
their associations’ statistical power, and the ranks an index obtained for its associations with all the tested SNPs (or a subset)
were summed up resulting in a final ranking. This approach revealed area under the curve (AUC)Insulin(0-30)/AUCGlucose(0-30) as
the best-ranked index to detect SNP-dependent differences in insulin release. Moreover, AUCInsulin(0-30)/AUCGlucose(0-30),
corrected insulin response (CIR), AUCC-Peptide(0-30)/AUCGlucose(0-30), AUCC-Peptide(0-120)/AUCGlucose(0-120), two different formulas
for the incremental insulin response from 0–30 min, i.e., the insulinogenic indices (IGI)2 and IGI1, and insulin 30 min were
significantly higher-ranked than homeostasis model assessment of b-cell function (HOMA-B; p,0.05). AUCC-Peptide(0-120)/
AUCGlucose(0-120) was best-ranked for the detection of SNPs involved in incretin-stimulated insulin secretion. In all analyses,
HOMA-b displayed the highest rank sums and, thus, scored last.
Conclusions/Significance: With AUCInsulin(0-30)/AUCGlucose(0-30), CIR, AUCC-Peptide(0-30)/AUCGlucose(0-30),A U C C-Peptide(0-120)/
AUCGlucose(0-120), IGI2, IGI1, and insulin 30 min, dynamic measures of insulin secretion based on early insulin and C-peptide
responses to oral glucose represent measures which are more appropriate to assess genetically determined b-cell
dysfunction than fasting measures, i.e., HOMA-B. Genes predominantly influencing the incretin axis may possibly be best
detected by AUCC-Peptide(0-120)/AUCGlucose(0-120).
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Introduction
Recently, genome-wide association (GWA) scans in tens of
thousands of human cases and controls using high-density single
nucleotide polymorphism (SNP) arrays and subsequent meta-
analyses of these data provided important new insights into the
genetic architecture of complex diseases [1]. In the course of these
studies, a series of nearly 20 novel type 2 diabetes risk loci were
identified. In smaller but extensively and thoroughly phenotyped
cohorts, many of the diabetogenic alleles were shown to affect b-
cell function [2]. Despite this recent scientific progress, a
shortcoming of the genetic findings up to now is that the sum of
all reported common GWA-derived risk alleles only marginally
improves the prediction of future type 2 diabetes, when combined
with established clinical parameters, and only explains about 6%
of the heritability of the disease [3]. Thus, it is anticipated that
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14194many more loci remain to be discovered that act in an additive or
even synergistic manner to increase the type 2 diabetes risk.
Amongst others, the following strategies are currently discussed to
find them: (i) use of SNP arrays of higher density, (ii) assessment of
rare variants, and (iii) realization of GWA analyses using
quantitative traits known to be crucially involved in the
pathogenesis of type 2 diabetes, such as insulin secretion and
insulin sensitivity [2;3].
One possibility to identify more loci affecting b-cell function is
to determine insulin release in cohorts large enough to allow
reliable genetic analyses. To estimate insulin release in such
cohorts with reasonable effort, i.e., at low expenses in time and
costs, fasting state- and several different oral glucose tolerance test
(OGTT)-derived indices calculated from plasma insulin, C-
peptide, and glucose concentrations are available [4–10]. Howev-
er, which of these indices are best-suited to detect genetically
determined b-cell dysfunction is unknown. Therefore, we
evaluated, in this study, fasting state- (homeostasis model assessment
of b-cell function [HOMA-B]) and OGTT-derived indices (insulin
and C-peptide concentrations at 30 min of OGTT, insulin-
ogenic indices [IGIs], area under the curve [AUC]Insulin(0-30)/
AUCGlucose(0-30),A U C C-Peptide(0-30)/AUCGlucose(0-30),A U C Insulin(0-120)/
AUCGlucose(0-120),A U C C-Peptide(0-120)/AUCGlucose(0-120),o r a ld i s p o s i -
tion index [DI oral], corrected insulin response [CIR], and first-
phase insulin secretion) for their suitability to detect altered insulin
release due to confirmed type 2 diabetes risk SNPs convincingly
described toaffectspecificaspects ofb-cellfunction, suchasglucose-
stimulated insulin secretion (GSIS), incretin-stimulated insulin
secretion (ISIS), or incretin release. For this investigation, we
included the type 2 diabetes risk loci/SNPs MTNR1B rs10830963,
HHEX rs7923837, CDKAL1 rs7754840, TCF7L2 rs7903146, WFS1
rs10010131, and KCNQ1 rs151290.
Materials and Methods
Ethics statement
From all participants, informed written consent to the study was
obtained, and the Ethics Committee of the Medical Faculty of the
University of Tu ¨bingen approved the study protocol.
Subjects
A cohort of 1364 White individuals was recruited from the
ongoing Tu ¨bingen family study for type 2 diabetes (TU ¨F) that
currently encompasses ,2000 participants at increased risk for
type 2 diabetes (non-diabetic individuals from Southern Germany
with family history of type 2 diabetes or diagnosis of impaired
fasting glycaemia) [11]. More than 99.5% of the TU ¨F participants
are of European ancestry. All participants underwent the standard
procedures of the study protocol including medical history and
physical examination, assessment of smoking status and alcohol
consumption habits, routine blood tests, and an OGTT. Selection
of the present study cohort was based on the absence of newly
diagnosed diabetes and the availability of complete sets of clinical
and genotype data. Moreover, the participants were not taking any
medication known to affect glucose tolerance or insulin secretion.
The subject characteristics are given in Table 1. From this cohort,
a subset of 274 individuals additionally underwent a frequently
sampled intravenous glucose tolerance test (IVGTT).
OGTT and IVGTT
A standard 75-g OGTT was performed after a ten-hour
overnight fast, and venous blood samples were drawn at time-
points zero, 30, 60, 90, and 120 min for the determination of
plasma glucose, insulin, and C-peptide concentrations. In those
individuals who agreed to undergo the IVGTT, baseline samples
(-10, -5, and 0 min) were collected before a glucose dose of 0.3 g/
kg body weight was given. Blood samples for the measurement of
plasma glucose and insulin were obtained at 2, 4, 6, 8, 10, 20, 30,
40, 50, and 60 min.
Laboratory measurements
Plasma glucose was determined using a bedside glucose analyzer
(glucose oxidase method, Yellow Springs Instruments, Yellow
Springs, OH, USA). Plasma insulin and C-peptide concentrations
were measured by commercial chemiluminescence assays for
ADVIA Centaur (Siemens Medical Solutions, Fernwald, Ger-
many) according to the manufacturer’s instructions.
Selection of loci/SNPs
From each confirmed type 2 diabetes risk locus previously
reported to affect specific aspects of b-cell function, we selected
one representative SNP based on the availability of genotype data
and on the robustness of the SNP’s b-cell effect in our cohort. As
loci/SNPs associated with GSIS, we selected MTNR1B
rs10830963 [12;13], HHEX rs7923837 [14;15], and CDKAL1
rs7754840 [16;17]. As loci/SNPs predominantly associated with
Table 1. Subject characteristics including the fasting state-
and OGTT-derived indices of insulin release (N=1364).
Count or Mean ±SD
Parameter NGT IFG IGT
Women/men (N) 661/331 83/54 95/33
Age (yrs) 37612 43613 41613
BMI (kg/m
2)2 7 . 2 66.9 31.7610.2 30.167.3
Fasting glucose (mmol/l) 4.9060.39 5.8460.25 5.1060.30
Glucose 120 min (mmol/l) 5.6161.13 6.2260.99 8.7160.76
Fasting insulin (pmol/l) 53.3643.1 80.5673.0 72.7652.7
Fasting C-peptide (pmol/l) 5786252 7736389 6736296
HOMA-b (U/mol)* 1346115 1166106 1536104
Insulin 30 min (pmol/l)* 4656375 5076369 5306397
C-Peptide 30 min (pmol/l)* 19926841 218261008 20406910
IGI1 (610
29)* 1646229 1486131 123693
IGI2 (610
29)* 51.5641.6 46.7636.0 50.5638.4
DI oral (mmol
21)* 3.6765.86 2.1961.88 1.9061.19
CIR (l6mmol
21610
29)* 164261450 11416943 12046866
First-phase insulin secretion
(pmol/l)*
12346784 12476893 12806865
AUCInsulin(0-30)/AUCGlucose(0-30)
(610
29)*
40.0630.3 39.3628.6 42.5629.8
AUCInsulin(0-120)/AUCGlucose(0-120)
(610
29)*
58.6642.4 63.9641.3 66.9650.1
AUCC-Peptide(0-30)/AUCGlucose
(610
29)*
201677 198685 192675
AUCC-Peptide(0-120)/AUCGlucose(0-120)
(610
29)*
3246105 3226116 2896100
*Seventeen subjects with calculated negative values in one or more of the
twelve insulin secretion indices tested were excluded (N=1347). AUC – area
under the curve; BMI – body mass index; CIR – cleared insulin response; DI –
disposition index; HOMA-B – homeostasis model assessment of beta-cell
function; IFG – impaired fasting glycaemia; IGI – insulinogenic index; IGT –
impaired glucose tolerance; NGT – normal glucose tolerance; OGTT – oral
glucose tolerance test.
doi:10.1371/journal.pone.0014194.t001
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WFS1 rs10010131 [20], and KCNQ1 rs151290 [21]. All SNPs were
genotyped in the whole cohort in the course of earlier studies
[12;15;17;18;20;21] using TaqMan assays (Applied Biosystems,
Foster City, CA, USA) and passed the quality controls. Details on
this as well as on minor allele frequencies, genotyping success
rates, and Hardy-Weinberg equilibrium are reported in the
aforementioned references.
Calculations
Insulin secretion derived from the fasting state was calculated as
HOMA-B: 20?I0/(G0–3.5) with I0=fasting insulin in mU/ml and
G0=fasting glucose in mmol/l [5]. All other insulin secretion
indices were derived from the OGTT with insulin and C-peptide
concentrations given in pmol/l, and glucose concentration given in
mmol/l. AUCs of insulin, C-peptide, and glucose concentrations
during the entire 120 min of the OGTT were calculated accord-
ing to the trapezoid method as: 0.5?(0.5?c0+c30+c60+c90+
0.5?c120) with c=concentration. AUCInsulin(0-30)/AUCGlucose(0-30)
was calculated as: (I0+I30)/(G0+G30) [9]. AUCC-Peptide(0-30)/
AUCGlucose(0-30) was calculated analogously. IGI1 was calculated
as: (I30–I0)/(G30–G0) [10]. IGI2 was calculated as: (I30–I0)/G30 [6].
DI oral was calculated as: IGI1/I0 [8]. CIR was calculated as:
100?I30/[G30?(G30–3.89)] [4]. First-phase insulin secretion was
calculated as: 1283+1.829?I30–138.7?G30+3.772?I0 [7]. Insulin
sensitivity derived from the OGTT was estimated as proposed by
Matsuda and DeFronzo [22]: 10000/(G0?I0?Gmean?Imean)
K. Fasting
insulin clearance was calculated as CP0/I0 with CP0=fasting C-
peptide, insulin clearance during the OGTT was calculated as
AUCC-Peptide(0-120)/AUCInsulin(0-120). Acute insulin response (AIR)
derived from the IVGTT was used as gold standard for the
assessment of insulin secretion and calculated as:
0.5?(0.5?I0+I2+I4+I6+I8+0.5?I10).
Statistical analyses
Prior to analysis, all continuous data were loge-transformed in
order to approximate normal distribution. Multiple linear regres-
sion analysis was performed using the least-squares method. In the
regression models, the insulin secretion parameter was chosen as
dependent variable, the SNP genotype (additive inheritance model)
as independent variable, and gender, age, BMI, and OGTT-
derived insulin sensitivity as confounding variables. In addition, the
SNP genotype (additive inheritance model) was tested as dependent
variable and the insulin secretion parameter as independent
variable with inclusion of the aforementioned confounders in the
models. Since the critical confounding variables age, BMI, and
OGTT-derived insulin sensitivity did not achieve normal distribu-
tion even after applying the ladder of powers (probably due to the
inclusion/exclusioncriteria ofourstudy), weadditionally performed
linear regression models including these parameters as nominal
variables after stratification into quartiles. A p-value #0.05 was
considered statistically significant. Multiple linear regression
analyses, post hoc power calculations [statistical power (1-b)a n d
least significant number (lsn; i.e., the sample size expected to be
needed to achieve statistical significance) to detect the effect size
given by the default settings (square root of the sum of squares for
the hypothesis divided by N)], and Wilcoxon rank sum tests were
performed using the statistical software package JMP 4.0 (SAS
Institute, Cary, NC, USA).
Results
Seventeen subjects with calculated negative values in single
insulin secretion measures were excluded from all analyses
resulting in a final cohort of 1347 individuals. Since the phenotype
(insulin release) is determined by the genotype, we started our
analyses using the insulin secretion index as dependent variable
and the SNP genotype (additive inheritance model) as independent
variable. As expected, all tested loci/SNPs were significantly
associated with at least two of the indices after adjustment for the
confounding variables gender, age, BMI, and OGTT-derived
insulin sensitivity (p#0.05, Table 2; additional statistical data
given in Table S1). Most secretion indices identified three, four, or
five of the six tested loci/SNPs to be significantly associated with
insulin release, whereas HOMA-B detected MTNR1B rs10830963
only. Inclusion of the confounding parameters age, BMI, and
OGTT-derived insulin sensitivity as nominal variables (after
stratification into quartiles) in the linear regression models resulted
in very similar statistical data (Table S2). After adjustment for
gender, age, and BMI, none of the SNPs showed significant
association with insulin clearance either in the fasting state (p.0.1)
or during the OGTT (p$0.06).
To evaluate which indices are most appropriate to detect
genetically determined differences in insulin release, we first
calculated the post hoc least significant numbers for all associations
and converted them into ranks with indices that displayed the
lowest least significant number being the best-ranked (Table 2).
Then, we summed up the ranks of each insulin secretion index
obtained for all the tested SNPs and ranked the indices according
to their rank sums (Table 3). Using this approach, AUCInsulin(0-30)/
AUCGlucose(0-30) was identified as the best-ranked index (Table 3).
Moreover, AUCInsulin(0-30)/AUCGlucose(0-30),C I R ,A U C C-Peptide(0-30)/
AUCGlucose(0-30),A U C C-Peptide(0-120)/AUCGlucose(0-120),I G I 2,I G I 1,
and insulin 30 min, but not C-peptide 30 min, first-phase insulin
secretion, AUCInsulin(0-120)/AUCGlucose(0-120), or DI oral, were
significantly higher-ranked than HOMA-B (p,0.05; Table 3). To
avoid over-adjustment of DI oral, a secretion parameter already
normalised for a rough estimate of insulin sensitivity (i.e., fasting
insulin), this parameter was also tested in the absence of additional
adjustment for OGTT-derived insulin sensitivity. This analysis
resulted in a somewhat higher rank sum (57) that, however, had no
impact on this index’ overall rank (rank 11). When summing up
the ranks of the indices obtained for the three loci/SNPs affecting
GSIS, i.e., MTNR1B rs10830963, HHEX rs7923837, and CDKAL1
rs7754840, AUCInsulin(0-30)/AUCGlucose(0-30) again turned out to be
the highest-ranked index (Table 3). Notably, when summing up
the ranks obtained for the three loci/SNPs predominantly
affecting ISIS, i.e., TCF7L2 rs7903146, WFS1 rs10010131, and
KCNQ1 rs151290, AUCC-Peptide(0-120)/AUCGlucose(0-120) was the
best-ranked index (Table 3). In the GSIS and ISIS subgroups,
statistical analysis of the rankings was inappropriate due to the
small sample sizes. In all rankings, HOMA-b displayed the highest
rank sums and, thus, represented the lowest-ranked index.
Assessing the SNP genotype (additive inheritance model) as
dependent variable and the insulin secretion parameter as
independent variable with inclusion of the aforementioned
confounders in the multiple regression models yielded very similar
rankings (Tables S3 and S4).
Interestingly, the indices that performed best in all these
analyses, i.e., AUCInsulin(0-30)/AUCGlucose(0-30) and CIR, also
revealed the best correlations with IVGTT-derived AIR (both
r=0.76), and HOMA-B, the lowest ranked index, showed the
weakest correlation with AIR (r=0.64, N=274; Table 4).
Discussion
In this study, we intended to identify, among twelve fasting
state- and common (or recently introduced) OGTT-derived
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best-suited to detect genetically determined alterations of insulin
release. Since the suitability of the indices for detection of altered
b-cell function may depend on the SNPs’ pathomechanisms, we
additionally analysed the SNPs affecting GSIS separately from
those affecting the incretin axis (ISIS or incretin release). It was not
the primary aim of this study to evaluate the performance of the
fasting state- and OGTT-derived estimates of insulin secretion by
comparing them with gold standard measures derived from
laborious and expensive methods, such as IVGTT or hypergly-
cemic clamp.
Using summation of the ranks derived from post hoc least
significant numbers, we show here that AUCInsulin(0-30)/AUCGlu-
cose(0-30), a recently proposed index validated against first-phase
insulin release in a frequently sampled IVGTT [9], represents the
best-ranked index for the detection of SNP effects on overall
insulin release as well as on GSIS. By contrast, loci/SNPs affecting
the incretin axis may be better captured by AUCC-Peptide(0-120)/
AUCGlucose(0-120). One explanation for this divergent result is that
plasma concentrations of incretins, as compared to plasma glucose,
do not rapidly decline after having reached their maximum during
the first 60 min of the OGTT, but remain elevated until the end of
the protocol [18;21]. Thus, OGTT-induced levels of incretins,
comparedtoglucose,mayexertmore prolongedeffectsontheb-cell
which are best assessed using indices covering the entire OGTT
period. The observation that AUCInsulin(0-120)/AUCGlucose(0-120) is
not among the best-suited indices to detect alterations of the incretin
axis may be due to the shorter circulating half-life of insulin as
compared to C-peptide [23].
AUCInsulin(0-30)/AUCGlucose(0-30), CIR, AUCC-Peptide(0-30)/
AUCGlucose(0-30), AUCC-Peptide(0-120)/AUCGlucose(0-120), IGI2, IGI1,
and insulin 30 min significantly outperformed HOMA-B in the
detection of genetically determined differences in overall insulin
release, and thus are clearly superior to HOMA-B in this regard.
Since the ranks of C-peptide 30 min, first-phase insulin secretion,
AUCInsulin(0-120)/AUCGlucose(0-120), and DI oral were statistically
indistinguishable from that of HOMA-B – and HOMA-B
displayed the lowest ranks in all analyses –, these indices may
not be recommended for genetic studies aimed at the identification
of novel loci/SNPs affecting b-cell function. The validity of the
OGTT-derived index AUCInsulin(0-30)/AUCGlucose(0-30) as a pref-
erable proxy for the assessment of b-cell function in large genetic
studies is underscored by its strong correlation with IVGTT-
Table 4. Association of the fasting- and OGTT-derived indices
of insulin release with IVGTT-derived AIR (N=274).
AIR
Parameter r p
AUCInsulin(0-30)/AUCGlucose(0-30) 0.76 ,0.0001
CIR 0.76 ,0.0001
IGI2 0.75 ,0.0001
First-phase insulin secretion 0.74 ,0.0001
IGI1 0.72 ,0.0001
AUCC-Peptide(0-30)/AUCGlucose(0-30) 0.72 ,0.0001
Insulin 30 min 0.71 ,0.0001
DI oral 0.70 ,0.0001
AUCInsulin(0-120)/AUCGlucose(0-120) 0.70 ,0.0001
C-Peptide 30 min 0.68 ,0.0001
AUCC-Peptide(0-120)/AUCGlucose(0-120) 0.67 ,0.0001
HOMA-b 0.64 ,0.0001
Prior to multiple linear regression analysis, all continuous variables were loge-
transformed to approximate normal distribution. In the multiple linear
regression models, AIR was chosen as dependent variable, the fasting-/OGTT-
derived insulin secretion index as independent variable and gender, age, BMI,
and OGTT-derived insulin sensitivity as confounding variables. AIR – acute
insulin response; AUC – area under the curve; CIR – cleared insulin response; DI
– disposition index; HOMA-B – homeostasis model assessment of beta-cell
function; IGI – insulinogenic index; IVGTT – intravenous glucose tolerance test;
OGTT – oral glucose tolerance test.
doi:10.1371/journal.pone.0014194.t004
Table 3. Ranking of the indices of insulin release according to their rank sums.
Overall ranking
(all SNPs tested)
Ranking for detection of GSIS
(MTNR1B, HHEX, and CDKAL1 SNPs)
Ranking for detection of ISIS
(TCF7L2, WFS1, and KCNQ1 SNPs)
Rank Parameter
Rank sum
(from lsn) Rank Parameter
Rank sum
(from lsn) Rank Parameter
Rank sum
(from lsn)
1 AUCInsulin(0-30)/AUCGlucose(0-30) 24* 1 AUCInsulin(0-30)/AUCGlucose(0-30) 7 1 AUCC-Peptide(0-120)/AUCGlucose(0-120) 6
2 CIR 28* 2 CIR 10 2 AUCC-Peptide(0-30)/AUCGlucose(0-30) 9
3 AUCC-Peptide(0-30)/AUCGlucose(0-30) 29* 3 IGI2 13 3 C-Peptide 30 min 14
AUCC-Peptide(0-120)/AUCGlucose(0-120) 29* 4 First-phase insulin secretion 16 4 IGI1 17
5I G I 2 33* 5 Insulin 30 min 17 AUCInsulin(0-30)/AUCGlucose(0-30) 17
6I G I 1 36* 6 IGI1 19 6 CIR 18
7 C-Peptide 30 min 39 7 AUCC-Peptide(0-30)/AUCGlucose(0-30) 20 7 IGI2 20
8 Insulin 30 min 42* 8 AUCC-Peptide(0-120)/AUCGlucose(0-120) 23 8 AUCInsulin(0-120)/AUCGlucose(0-120) 22
First-phase insulin secretion 42 9 AUCInsulin(0-120)/AUCGlucose(0-120) 24 9 Insulin 30 min 25
10 AUCInsulin(0-120)/AUCGlucose(0-120) 46 10 C-Peptide 30 min 25 10 First-phase insulin secretion 26
11 DI oral 55 DI oral 25 11 DI oral 30
12 HOMA-b 64 12 HOMA-B 34 HOMA-B 30
*Significantly different from HOMA-B (p,0.05; Wilcoxon rank sum test). AUC – area under the curve; CIR – cleared insulin response; DI – disposition index; GSIS –
glucose-stimulated insulin secretion; HOMA-B – homeostasis model assessment of beta-cell function; IGI – insulinogenic index; ISIS – incretin-stimulated insulin
secretion/incretin production; lsn – least significant number; SNP – single nucleotide polymorphism.
doi:10.1371/journal.pone.0014194.t003
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PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e14194derived AIR. In these latter analyses with IVGTT-derived AIR as
gold standard, HOMA-B again revealed the weakest correlation
and, thus, was confirmed to be less useful for the detection of
impaired b-cell function.
A limitation of our study is that the results were generated in a
single study population and, thus, clearly need replication in other
comparably genotyped and phenotyped cohorts of similar or
larger sample size. Furthermore, the ranking of the insulin
secretion indices may also depend on the ethnicity. Since our
study cohort was nearly exclusively comprised of White European
subjects, similar analyses in other ethnicities would be interesting.
Finally, we conclude that, according to our data, AUCInsulin(0-30)/
AUCGlucose(0-30), along with CIR, AUCC-Peptide(0-30)/AUCGlucose(0-30),
AUCC-Peptide(0-120)/AUCGlucose(0-120),I G I 2,I G I 1,a n di n s u l i n3 0m i n ,
represents an appropriate surrogate parameter to assess genetically
determined b-cell dysfunction. HOMA-B, DI oral, AUCInsulin(0-120)/
AUCGlucose(0-120), first-phase insulin secretion, and C-peptide 30 min,
however, are of limited informative value for genetic studies on b-cell
functioninhumans.TheinfluenceofgenesonISISorincretinrelease
may possibly be better detected by calculating AUCC-Peptide/
AUCGlucose. These findings, if replicated in comparably sized and
phenotyped cohorts, should facilitate the identification of novel loci/
SNPs affecting insulin release in large cohorts metabolically
characterized by OGTT with glucose, insulin, and C-peptide
measurements.
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Table S1 Additional statistical data of the SNPs’ associations
with indices of insulin release. Given are the estimate and the
standard deviation of the minor allele’s effect. Seventeen subjects
with calculated negative values were excluded (N=1347). Prior to
multiple linear regression analysis, all continuous variables were
loge-transformed to approximate normal distribution. In the
multiple linear regression models, the insulin secretion parameter
was chosen as dependent variable, the SNP genotype (additive
inheritance model) as independent variable and gender, age, BMI,
and OGTT-derived insulin sensitivity as confounding variables.
AUC - area under the curve; BMI - body mass index; CIR -
cleared insulin response; DI - disposition index; HOMA-B -
homeostasis model assessment of beta-cell function; IGI -
insulinogenic index; SD - standard deviation; SNP - single
nucleotide polymorphism.
Found at: doi:10.1371/journal.pone.0014194.s001 (0.07 MB
DOC)
Table S2 Statistical data of the SNPs’ associations with indices
of insulin release using the covariates age, BMI, and OGTT-
derived insulin sensitivity as nominal variables (stratified in
quartiles). Given are the p-value, estimate and the standard
deviation of the minor allele’s effect. Seventeen subjects with
calculated negative values were excluded (N=1347). In the
multiple linear regression models, the insulin secretion parameter
was chosen as dependent variable, the SNP genotype (additive
inheritance model) as independent variable and gender, age, BMI,
and OGTT-derived insulin sensitivity as confounding variables.
AUC - area under the curve; BMI - body mass index; CIR -
cleared insulin response; DI - disposition index; HOMA-B -
homeostasis model assessment of beta-cell function; IGI -
insulinogenic index; SD - standard deviation; SNP - single
nucleotide polymorphism.
Found at: doi:10.1371/journal.pone.0014194.s002 (0.07 MB
DOC)
Table S3 Statistical data of the SNPs’ associations with indices
of insulin release using the genotype as dependent variable.
Seventeen subjects with calculated negative values were excluded
(N=1347). Prior to multiple linear regression analysis, all
continuous variables were loge-transformed to approximate
normal distribution. In the multiple linear regression models, the
SNP genotype (additive inheritance model) was chosen as
dependent variable, the insulin secretion parameter as indepen-
dent variable and gender, age, BMI, and OGTT-derived insulin
sensitivity as confounding variables. AUC - area under the curve;
BMI - body mass index; CIR - cleared insulin response; DI -
disposition index; HOMA-B - homeostasis model assessment of
beta-cell function; IGI - insulinogenic index; lsn - least significant
number (sample size expected to be needed to achieve statistical
significance); SNP - single nucleotide polymorphism.
Found at: doi:10.1371/journal.pone.0014194.s003 (0.08 MB
DOC)
Table S4 Ranking of the indices of insulin release according to
their rank sums derived from the statistics presented in
Supplemental Table S3 (genotype as dependent variable). *
Significantly different from HOMA-B (p,0.05; Wilcoxon rank
sum test). AUC - area under the curve; CIR - cleared insulin
response; DI - disposition index; GSIS - glucose-stimulated insulin
secretion; HOMA-B - homeostasis model assessment of beta-cell
function; IGI - insulinogenic index; ISIS - incretin-stimulated
insulin secretion/incretin production; lsn - least significant
number; SNP - single nucleotide polymorphism.
Found at: doi:10.1371/journal.pone.0014194.s004 (0.06 MB
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